At 4.9% CAGR, the Asia Pacific Endothelial Dysfunction Market is Projected to be Worth US$ 405.51 million by 2028, says The Business Market Insights

According to the Business Market Insights research, the Asia Pacific endothelial dysfunction market was valued at US$ 304.48 million in 2022 and is expected to reach US$ 405.51 million by 2028, registering a CAGR of 4.9% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes, and obesity are the critical factors attributed to the Asia Pacific endothelial dysfunction market expansion.

Lifestyle changes lead to a rise in the incidences of diabetes, hypertension, dyslipidemia, and obesity, increasing the chances of endothelial dysfunction. However, these can be prevented through proactive monitoring, early diagnosis, and physical activity. Metabolic syndrome is a group of disorders that increases the risk of CAD, diabetes, high blood pressure, and other serious health problems. Type 2 diabetes is already a major public health problem and is increasingly rising among the children and young adults associated with obesity. According to the World Health Organization (WHO), diabetes was the direct cause of 1.5 million deaths in 2019, and 48% of all deaths from diabetes occurred before age 70. Another 460,000 deaths from kidney disease were caused by diabetes. Elevated blood sugar causes ~20% of cardiovascular deaths.

According to the WHO, ~38.2 million children under five were overweight or obese in 2019 worldwide. Of them, almost half were in Asia. Overweight and obesity, once considered a problem in high-income countries, is now increasing in low- and middle-income countries, particularly in urban areas.

According to the WHO, high cholesterol caused an estimated 2.6 million deaths in 2022. High cholesterol is one of the major contributors to disease burden in developed and developing countries and a risk factor for heart disease. Increased consumption of high-fat and high-sugar foods and physical immobility due to inactivity in different types of work, changing modes of transportation, and increasing urbanization all contribute to the growth of diseases such as diabetes, obesity, cholesterol, and high blood pressure. Therefore, the growing prevalence of such diseases is boosting the endothelial dysfunction market growth.

On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of Asia Pacific endothelial dysfunction market.

Based on cause, the Asia Pacific endothelial dysfunction market is segmented into hypertension, hypercholestrolaemia, obesity, diabetes, Behcet's disease, and others. The hypertension segment held 32.8% share of Asia Pacific endothelial dysfunction market in 2022, amassing US$ 99.95 million. It is projected to garner US$ 136.94 million by 2028 to expand at 5.4% CAGR during 2022-2028.

Based on test type, the Asia Pacific endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 73.9% share of Asia Pacific endothelial dysfunction market in 2022, amassing US$ 224.92 million. It is projected to garner US$ 295.38 million by 2028 to expand at 4.6% CAGR during 2022-2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the Asia Pacific endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held 51.9% share of Asia Pacific endothelial dysfunction market in 2022, amassing US$ 158.00 million. It is projected to garner US$ 214.58 million by 2028 to expand at 5.2% CAGR during 2022-2028.

Based on country, the Asia Pacific endothelial dysfunction market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.3% share of Asia Pacific endothelial dysfunction market in 2022. It was assessed at US$ 92.23 million in 2022 and is likely to hit US$ 128.53 million by 2028, exhibiting a CAGR of 5.7% during 2022-2028.

Key players operating in the Asia Pacific endothelial dysfunction are ZOLL Medical Corp, Sphingo Tec GmbH, Perimed AB, and Medizinische Messtechnik GmbH, among others.

- In July 2020, SphingoTec launched point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction. The company launched its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com